Gemphire Therapeutics, Inc. News Releases http://ir.gemphire.com/ Gemphire Therapeutics, Inc. News Releases en Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2018 Financial Results http://ir.gemphire.com/news-releases/news-release-details/gemphire-therapeutics-reports-fourth-quarter-and-fiscal-year-0 LIVONIA, Mich. , March 15, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening Fri, 15 Mar 2019 08:00:00 -0400 Gemphire Therapeutics, Inc. News Releases 7961 Gemphire Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update http://ir.gemphire.com/news-releases/news-release-details/gemphire-therapeutics-announces-review-strategic-alternatives LIVONIA, Mich., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), today announced Mon, 03 Dec 2018 08:00:00 -0500 Gemphire Therapeutics, Inc. News Releases 7941 Gemphire Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update http://ir.gemphire.com/news-releases/news-release-details/gemphire-therapeutics-reports-third-quarter-2018-financial     LIVONIA, Mich., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), today Thu, 08 Nov 2018 16:01:00 -0500 Gemphire Therapeutics, Inc. News Releases 7946 Gemphire Therapeutics Announces Workforce Reduction http://ir.gemphire.com/news-releases/news-release-details/gemphire-therapeutics-announces-workforce-reduction     LIVONIA, Mich., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), announces Mon, 24 Sep 2018 17:06:00 -0400 Gemphire Therapeutics, Inc. News Releases 7951 Gemphire Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update http://ir.gemphire.com/news-releases/news-release-details/gemphire-therapeutics-reports-second-quarter-2018-financial LIVONIA, Mich. , Aug. 13, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), today announced Mon, 13 Aug 2018 16:01:00 -0400 Gemphire Therapeutics, Inc. News Releases 7831 Gemphire Announces Termination of Phase 2a Clinical Trial of Gemcabene in Pediatric NAFLD http://ir.gemphire.com/news-releases/news-release-details/gemphire-announces-termination-phase-2a-clinical-trial-gemcabene LIVONIA, Mich. , Aug. 10, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), announces today Fri, 10 Aug 2018 06:00:00 -0400 Gemphire Therapeutics, Inc. News Releases 7826 Gemphire Provides Update On Development of Gemcabene http://ir.gemphire.com/news-releases/news-release-details/gemphire-provides-update-development-gemcabene FDA requests the Company provide additional data regarding the partial clinical hold Company continues Phase 2 development of gemcabene for NAFLD/NASH Company amends loan agreement with SVB to provide additional flexibility Conference call and webcast today, Monday, August 6 , at 4:30 p.m. Mon, 06 Aug 2018 17:18:54 -0400 Gemphire Therapeutics, Inc. News Releases 7821 Gemphire Announces Amended and Restated Gemcabene License Agreement with Pfizer Inc. http://ir.gemphire.com/news-releases/news-release-details/gemphire-announces-amended-and-restated-gemcabene-license LIVONIA, Mich., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), today announced Mon, 06 Aug 2018 16:00:00 -0400 Gemphire Therapeutics, Inc. News Releases 7816 Gemcabene Meets Primary Endpoint in INDIGO-1 Study of Severe Hypertriglyceridemia (SHTG) Patients http://ir.gemphire.com/news-releases/news-release-details/gemcabene-meets-primary-endpoint-indigo-1-study-severe Gemcabene demonstrated statistically significant lowering of triglycerides (TGs) in SHTG Secondary endpoints achieved included statistically significant reductions in serum LDL-C, non-HDL-C, VLDL-C, apoB, apoE, apoCIII, and SAA Gemcabene showed evidence of safety and tolerability in combination Thu, 28 Jun 2018 16:01:26 -0400 Gemphire Therapeutics, Inc. News Releases 7761 Gemphire Therapeutics Provides the American Liver Foundation an Educational Grant in Support of Disease State Awareness for Pediatric NAFLD http://ir.gemphire.com/news-releases/news-release-details/gemphire-therapeutics-provides-american-liver-foundation-0 LIVONIA, Mich., May 17, 2018 -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and Fri, 18 May 2018 09:30:00 -0400 Gemphire Therapeutics, Inc. News Releases 7756